Phase 2 N=35 Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
Breast Cancer
Primary: Objective Response Rate (ORR) — 37.5 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=38 Assessing Arrhythmias After Ablation Using Implantable Recorders
Atrial Fibrillation
Primary: Arrhythmia Burden — 7; 18; 18; 5 Participants
Phase 4 N=102 Efficacy of Peri-Incisional Multimodal Drug Injection Following Operative Management of Femur Fractures
Pain, Postoperative · Femur Fracture
Primary: Visual Analog Scale Pain Assessment — 5.0; 5.0; 1.6; 3.2 units on a scale
Phase 2 N=10 Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy
Urinary Tract Infection · Vesicoureteral Reflux
Primary: Visualization of Renal Scars Compared to Previous Imaging — 100 Percentage of previous scars visualized
N/A N=61 Sapphire II PRO US Clinical Study
Coronary Artery Disease · Coronary Disease · Myocardial Ischemia
Primary: Number of Participants With Device Procedural Success — 59 Participants
Phase 2 N=371 S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
Lymphoma · Nonneoplastic Condition
Primary: Percentage of HIV-negative Patients With 2-year Progression-free Survival (PFS) Treated With 2 Initial Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine…
N/A N=68 A Trial of E-cigarettes in Current Cigarette Smokers
Smoking · Nicotine Dependence · Nicotine Dependence, Other Tobacco Product
Primary: Uptake of Electronic Nicotine Delivery Systems (ENDS) — 57.14; 32; 13.64 percentage of participants
Phase 3 N=100 A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
Chronic Hepatitis C · HCV · Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 98 percentage of participants
N/A N=27 Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
Port Wine Stain
Primary: Change From Baseline in a* and E at 8 Weeks — 1.27; 0.43; 4.08; 2.59 units on a scale
Phase 4 N=29 Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men
Sarcopenia
Primary: Serum Total Testosterone Measured Before Treatment on Treatment Day 1 (Baseline Study) — 307.57; 363.43; 408.17; 318.68 ng/dL
Phase 2 N=9 Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
Alzheimer's Disease
Primary: Percent Change From Baseline to End of Treatment in Cerebrospinal Fluid Levels of Cytokines — 137 percentage of baseline at Day 42
N/A N=30 Evaluation of a New Sonoclot Device for Heparin Management in Cardiac Surgery
Diagnostic Techniques and Procedures · Cardiac Surgical Procedure
Primary: Kaolin-activated Clotting Time — 309 seconds
N/A N=55 Consumer Perception of an Experimental Mouthwash After a Single Use in Dry Mouth Subjects
Xerostomia
Primary: Number of Participants With Response to Post-Product Use Questionnaires 1 (PPUQ 1); Question No.1 — 1; 1; 5; 0 Participants
N/A N=27 Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
Macular Edema · Central Retinal Vein Occlusion
Primary: The Change in Visual Acuity (Number of ETDRS Early Treatment Diabetic Retinopathy Study Letters), at Month 6 as Compared With Baseline in Each Treatment Arm — 11.1; 16.1…
Phase 2 N=45 Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine
Episodic Migraine
Primary: Headache Days in Each Treatment Period Month — 7.1; 10.88; 7.05; 9.47 Number of Headache days